Interventional, randomised, double-blind, sequential-group, placebo-controlled single ascending dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF34134 in healthy young men and healthy elderly men and women, and open-label, three-period crossover, food interaction study of Lu AF34134 in healthy elderly men and women.

Interventional, randomised, double-blind, sequential-group, placebo-controlled single ascending dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF34134 in healthy young men and healthy elderly men and women, and open-label, three-period crossover, food interaction study of Lu AF34134 in healthy elderly men and women. - 14013A

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37707

Enrollment

102

Registered

2011-11-03

Start date

2011-11-14

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

The study will start with a screening. At the screening a physical examination will take place and a few other standard medical assessments will be performed (ECG, vital signs). Furthermore a blood

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy male and female

Exclusion criteria

Exclusion criteria: Clinical significant abnormalities at medical research

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Secondary

Measure	Time frame
Pharmacokinetics and pharmacodynamics	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)